California's Claret Medical lands FDA approval to conduct a pivotal trial of its Sentinel cerebral blood clot defense system in patients undergoing transcatheter aortic valve replacement.
Claret Medical is clear to launch a pivotal U.S. trial of its Sentinel cerebral protection system, having won FDA approval to evaluate the device in patients undergoing transcatheter aortic valve implantation.
The study is slated to begin in the 1st quarter of 2014 and will involve up to 15 clinical centers, Claret reported.
from MassDevice - FDA and Medical device business news and jobs for the medical device industry http://ift.tt/1nLlJoz
Cap comentari:
Publica un comentari a l'entrada